Arrowhead Pharmaceuticals Unveils Positive Clinical Data at EAS Congress
Decision brief
Answer first · skim in under a minute
Arrowhead Pharmaceuticals has presented promising clinical data on cardiometabolic disorders at the EAS Congress, signaling potential market opportunities.
Arrowhead Pharmaceuticals’ positive cardiometabolic data at the 94th EAS Congress focus on plozasiran practicality, not a new Phase 3 headline. On May 26, 2026, the company said 25 mg plozasiran can be used in moderate-to-severe renal impairment or moderate hepatic impairment without dose adjustment, and shared a familial chylomicronemia syndrome pregnancy case report.
Contents9 sections
Key Takeaways
- EAS 2026 (Athens, May 24–27) featured two Arrowhead oral presentations on plozasiran PK/PD/safety in renal or hepatic impairment and an FCS pregnancy case.
- Company conclusion: 25 mg supports use without dose adjustment in moderate-to-severe renal or moderate hepatic impairment; PD (APOC3 and TG reduction) matched controls despite modest exposure increases.
- No new safety signals were identified in the impairment study; future trials are still needed for advanced liver or renal disease.
- Phase 3 SHASTA-3/4/5 and MUIR-3 continue; FDA Breakthrough Therapy designation in severe hypertriglyceridemia was granted in December 2025.
What cardiometabolic data did Arrowhead unveil at EAS?
Arrowhead’s May 26, 2026 Business Wire release said new positive clinical data for investigational plozasiran were presented in two oral sessions at the 94th European Atherosclerosis Society Congress. One talk covered pharmacokinetics, pharmacodynamics, and safety in subjects with renal or hepatic impairment. The second was a case report of a pregnant woman with familial chylomicronemia syndrome treated with plozasiran, an siRNA against APOC3.
The impairment dataset is the load-bearing commercial signal: it addresses whether a fixed 25 mg regimen remains usable when organ function is reduced—common in real-world cardiometabolic care.
Source: Business Wire: Arrowhead plozasiran data at 94th EAS Congress.
How do the renal and hepatic impairment findings change labeling risk?
Despite modest increases in plozasiran exposure, pharmacodynamic responses—APOC3 and triglyceride reduction—were similar between control cohorts and those with moderate-to-severe renal or moderate hepatic impairment. Plozasiran was generally safe and well tolerated, with no new safety signals identified.
Arrowhead stated these data support 25 mg use without dose adjustment in those impairment categories, while calling for future trials in advanced liver or renal disease.
- Dose discussed: 25 mg plozasiran
- Congress: 94th EAS, Athens, May 24–27, 2026
- Breakthrough Therapy (sHTG): December 2025
- Phase 3 IDs: NCT06347003, NCT06347016, NCT06880770, NCT06347133
Source: Arrowhead EAS Business Wire release; ClinicalTrials.gov: SHASTA-3 NCT06347003.
What does the FCS pregnancy case report show—and not show?
The company said a case report suggests preconception exposure to plozasiran may be associated with sustained lowering of fasting triglycerides through the term of a pregnancy in FCS. That is a single-patient observation, not a controlled trial of use during pregnancy.
Investors should not treat the case as evidence of pregnancy safety or an approved indication. It is hypothesis-generating alongside the broader FCS/severe HTG program.
Source: Business Wire EAS release (pregnancy case language).
Pipeline context for cardiometabolic BD teams
Plozasiran remains in Phase 3 for severe hypertriglyceridemia (SHASTA-3, SHASTA-4, SHASTA-5) and hypertriglyceridemia (MUIR-3). The December 2025 Breakthrough Therapy designation in severe hypertriglyceridemia, disclosed in the EAS release, raises FDA interaction intensity but does not equal approval.
Related coverage: Arrowhead cardiometabolic data (related), Oligonucleotide therapeutics market, and FDA decisions Q2 2026.
What remains unproven
EAS impairment data do not replace Phase 3 outcomes on pancreatitis risk or long-term CV benefit. Advanced organ impairment safety, pregnancy use, and commercial dosing in those populations remain incompletely characterized per the company’s own caveats.
Related NovaPharma coverage
- Arrowhead positive cardiometabolic data
- Oligonucleotide therapeutics clinical trials
- Pharma M&A boom market analysis
Frequently Asked Questions
What plozasiran data did Arrowhead present at EAS 2026?
At the 94th EAS Congress (Athens, May 24–27, 2026), Arrowhead presented pharmacokinetics, pharmacodynamics, and safety of plozasiran in subjects with renal or hepatic impairment, plus a case report of a pregnant woman with familial chylomicronemia syndrome previously treated with plozasiran.
Does plozasiran need dose adjustment in renal or hepatic impairment?
Arrowhead reported that despite modest exposure increases, APOC3 and triglyceride reductions were similar to control cohorts, supporting use of the 25 mg dose in moderate-to-severe renal impairment or moderate hepatic impairment without dose adjustment; advanced disease still needs more study.
Which Phase 3 trials are evaluating plozasiran in hypertriglyceridemia?
Plozasiran is in SHASTA-3 (NCT06347003), SHASTA-4 (NCT06347016), and SHASTA-5 (NCT06880770) for severe hypertriglyceridemia and MUIR-3 (NCT06347133) for hypertriglyceridemia; FDA granted Breakthrough Therapy designation in severe hypertriglyceridemia in December 2025.
Primary Sources
Arrowhead Pharmaceuticals pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
